The DOI matches its Crossref record; the references it cites are not checked yet.
The Safety of HMG-CoA Reductase Inhibitors in Special Populations at High Cardiovascular Risk
Abstract
Controlled clinical studies and clinical experience over many years have proven that virtually all patients benefit from lipid-lowering therapy with statins, even those with normal LDL cholesterol levels. Several recent large outcome trials have further demonstrated the clinical benefits and safety of statins in patients with a wide-range of high risks for cardiovascular disease. Those patients at highest absolute cardiovascular risk generally have the most to gain from statin therapy. A variety of statins are available to lower plasma lipids to guideline levels, but all differ in their pharmacokinetic properties, drug interaction profiles, and risk of myotoxicity. This has been highlighted by the withdrawal of cerivastatin from the market as a result of serious safety concerns. This review examines the safety and effectiveness of statins in special populations at high risk of cardiovascular disease-patients with coronary heart disease, dyslipidaemia, diabetes, hypertension, nephrotic disease, HIV, organ transplant patients and the elderly-with a focus on clinically relevant differences in the properties of individual statins that may influence the risk of drug interactions and side effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several factors including female sex, ethnicity, multisystem disease, and small body frame predispose to SAMS, with the presence of an increasing number of factors associated with greater risk.
“Several factors including female sex, ethnicity, multisystem disease, and small body frame predispose to SAMS (see Box 1), with the presence of an increasing number of factors associated with greater risk.9,30,32–34”
Citations
The citation lists haven’t been fetched yet
References 286 · Cited by 82
Research works printed but not linked: 12
- Omar MA,Wilson JP,Cox TS. Rhabdomyolysis and HMGCoA reductase inhibitors. Ann Pharmacother 2001; 35: 1096-1107. · DOI · Paper page
- Farmer JA,Torre-Amione G. Comparative tolerability of the HMG-CoAreductase inhibitors. Drug Saf 2000; 108: 351-352.
- Omar MA,Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36: 288-295. · DOI · Paper page
- Shek A,Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35: 908-917. · DOI · Paper page
- Kanathur N,Mathai MG,Byrd RP Jr, et al. Simvastatindiltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001; 94: 339-341.
- Lee AJ,Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001; 35: 26-31. · DOI · Paper page
- Thompson GR. Poor responders to statins:Apotential target for stanol esters. Eur Heart J Suppl 1991; 1(Suppl S): S114-S117.
- Gruer PJ,Vega JM,Mercuri MF,Dobrinska MR,Tobert JA. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999; 84: 811-815. · DOI
- Peces R,Pobes A. Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron 2001; 89: 117-118. · DOI
- Regazzi MB,Iacona I,Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporinAin transplant recipients. Transplant Proc 1993; 25: 2732-2734.
- Rozenbaum W,Molina JM,Delfraissy JF, et al. Improvement of lipodystrophy in HIV-1 infected subjects switching from 2NRTI/PI to 2NRTI/abacavir (French substudy, CNA30017). 7th Conference on Retroviruses and Opportunistic Infections; Jan. 3-Feb. 2, 2000; San Francisco, California. Abstract 47.
- Fichtenbaum C,Gerber J,Rosenkranz S, et al. Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductase inhibitors. Presented at the 7th Conference on Retroviruses and Opportunistic Infections. Jan. 30-Feb. 2, 2000; San Francisco, California.
Metadata
- Authors
- Corsini, A.
- Affiliations
- University of Milan (IT)
- Corresponding author
- Corsini, Alberto
- ORCID
- Corsini, Alberto
- Venue
- Cardiovascular Drugs and Therapy
- Published
- 2003-05
- Volume
- 17
- Issue
- 3
- Pages
- 265-285
- ISSN
- 0920-3206 (ISSN-L)
- 1573-7241
- OpenAlex
- W2191544621
- Cited by
- 82
- References
- 286
- Citations by year
- 2025: 1 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 1 · 2018: 4 · 2017: 4 · 2016: 1 · 2015: 2 · 2013: 5 · 2012: 2
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Cardiovascular Drugs and Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- statins, drug safety, high cardiovascular risk, lipid-lowering therapy, drug interactions, myotoxicity, coronary artery disease, dyslipidemia, diabetes mellitus, hypertension, nephrotic syndrome, HIV, transplant recipients, elderly patients, statin pharmacokinetics
- MeSH terms
- Aged, Aged, 80 and over, Cardiovascular Diseases, Clinical Trials as Topic, Coronary Disease, Diabetes Mellitus, Type 2, Humans, Hyperlipidemias, Hypertension, Kidney Failure, Chronic, Rhabdomyolysis, Transplantation, HIV-1, HIV Infections, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
